



ATVIVO Laboratory
 955 Yonkers Ave STE 19
 Yonkers, NY 10704-3063
 CLIA ID: 33D2149086
 Medical Director PFI #: 9338

Toll free: (844) 788-1478
 Fax: (844) 674-2886
 Email: results@atvivo.com

Patient		Physician	
Last Name	Test	Last Name	Doctor
First Name	Test	First Name	TEST
Middle Name		Middle Name	X
Date of Birth	01/01/2001	NPI#	1234567890
MRN	123	Address	123 First Street,Apt 23 Brooklyn, NY 11205
Sex	Female		

Requisition ID	Collected	Received	Reported
210210AT004	2/10/2021 4:30 PM	2/10/21 4:31 PM	2/10/2021 4:36 PM

Testing Ordered	COVID TOTAL AB (IgG/IgM)
------------------------	--------------------------

COVID19

TEST	RESULT	FLAG	REF. RANGE
COVID TOTAL AB (IgG/IgM)	Nonreactive		Nonreactive

COVID AB IgG/IgM: This test is intended for the detection of SARS CoV-2 antibodies. Antibodies to SARS-CoV-2 are generally detectable in blood several days after initial infection, although the duration of time antibodies are present post-infection is not well characterized. Individuals may have detectable virus present for several weeks following seroconversion. At this time, it is unknown for how long antibodies persist following infection and if the presence of antibodies confers protective immunity. The sensitivity of the SARS-CoV-2 Total (COV2T) assay early after infection is unknown. Negative results do not preclude acute SARS-CoV-2 infection. If acute infection is suspected, direct testing for SARS-CoV-2 is necessary. False positive results for the SARS-CoV-2 Total (COV2T) assay may occur due to cross-reactivity from pre-existing antibodies or other possible causes.

The SARS-CoV-2 Total (COV2T) assay is only for use under the Food and Drug Administration's Emergency Use Authorization. This test has been authorized only for detecting the presence of antibodies against SARSCoV-2, not for any other viruses or pathogens. This test has not been FDA cleared or approved; the test has been authorized by FDA under an Emergency Use Authorization (EUA) for use by laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C 263a, to perform moderate or high complexity tests.

***** END OF REPORT *****

Laboratory Director	Ghazala Nathu, MS, MD, PhD, FACB
----------------------------	----------------------------------

ATVIVO

The above results and comments are for informational purposes only and are not to be interpreted as medical advice. Please consult your healthcare practitioner for diagnosis and treatment.